Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors. This study will also determine the RP2D of AGEN1181 monotherapy.
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti?CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer
- ClinicalTrials.gov Identifier: NCT03860272
- Protocol Number: 19-132
- Principal Investigator: Andrea Bullock
- Principal Investigator: Central PIO
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required